Xinqiao Hospital Of Chongqing
Clinical trials sponsored by Xinqiao Hospital Of Chongqing, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a simple CT scan be enough to decide stroke treatment? Results expected Jun 2027 (estimated)
-
Stroke showdown: which Pre-Clot drug wins?
Disease control CompletedThis study tests two different medicines given before a procedure to remove a blood clot from the brain in people having a major stroke. The goal is to see which medicine helps more people recover with little or no disability. About 800 adults who arrive at the hospital within 24…
Phase 2/3 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat head and neck cancer
Disease control CompletedThis trial tested a new treatment for people with Epstein-Barr virus (EBV)-positive head and neck cancer that has spread or come back. The treatment uses specially engineered immune cells (TCR-T cells) that recognize EBV on cancer cells and also release a PD1 blocker to help them…
Phase 1/2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat solid tumors
Disease control CompletedThis pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …
Phase 1/2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental immune therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…
Phase 1/2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental cell therapy takes on hard-to-treat throat cancer
Disease control CompletedThis early-phase trial tested a new type of cell therapy for people with advanced nasopharyngeal cancer linked to the Epstein-Barr virus. Nine patients received specially engineered immune cells (TCR-T cells) designed to recognize and attack the virus-infected cancer cells. The m…
Phase 1/2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take aim at HPV-Positive cancers
Disease control CompletedThis early-stage trial tested a new type of cell therapy for people with HPV-positive head & neck or cervical cancer. The treatment uses a patient's own immune cells, engineered to recognize and attack HPV-infected cancer cells. Some patients also received cells that produce an a…
Phase 1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC